Covered recipient · General Payments record
MAM IBRAHEEM
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2023
$664.59
- Reported across 31 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $369.75 | 17 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $195.27 | 9 |
| PFIZER INC. | $37.58 | 2 |
| SK Life Science, Inc. | $26.99 | 1 |
| Biogen, Inc. | $26.01 | 1 |
| Alnylam Pharmaceuticals Inc. | $24.49 | 1 |
| Teva Pharmaceuticals USA, Inc. | $23.57 | 1 |
| Amylyx Pharmaceuticals, Inc. | $21.72 | 1 |
| GE HEALTHCARE | $14.12 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.78 | 01/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527805 | CMS |
| ABBVIE INC. | $27.10 | 01/24/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527807 | CMS |
| ABBVIE INC. | $22.40 | 02/17/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527809 | CMS |
| ABBVIE INC. | $16.72 | 03/16/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527811 | CMS |
| ABBVIE INC. | $28.54 | 04/05/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527813 | CMS |
| ABBVIE INC. | $27.42 | 05/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527815 | CMS |
| ABBVIE INC. | $16.61 | 07/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527817 | CMS |
| ABBVIE INC. | $18.22 | 07/25/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527819 | CMS |
| ABBVIE INC. | $20.48 | 08/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 997527821 | CMS |
| Alnylam Pharmaceuticals Inc. | $24.49 | 04/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1006114823 | CMS |
| Amylyx Pharmaceuticals, Inc. | $21.72 | 02/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1057676541 | CMS |
| Biogen, Inc. | $26.01 | 04/10/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1012264839 | CMS |
| GE HealthCare | $14.12 | 02/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1039514549 | CMS |
| PFIZER INC. | $21.92 | 01/29/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1049100183 | CMS |
| PFIZER INC. | $15.66 | 05/01/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1049304333 | CMS |
| SK Life Science, Inc. | $26.99 | 07/14/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1054728813 | CMS |
| Teva Pharmaceuticals USA, Inc. | $23.57 | 06/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1056971069 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2022, 2023
- Source files
- Dataset page · Bulk file · PY2018 , PY2022 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.